Delving into the Latest Updates on Chlorpropamide with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

1-(p-chlorobenzenesulfonyl)-3-propylurea, 1-(p-chlorophenylsulfonyl)-3-propylurea, 1-propyl-3-(p-chlorobenzenesulfonyl)urea

+ [10]

Target

SUR

Action

agonists

Mechanism

SUR agonists(Sulfonylurea receptor agonists)

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

Diabetes Mellitus, Type 2

Inactive Indication-

Originator Organization

Pfizer Inc.

Active Organization

Xian Disai Biology Pharmaceutical Co. Ltd.

Inactive Organization

Pfizer Laboratories (Pty) Ltd.

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (28 Oct 1958),

Diabetes Mellitus, Type 2

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC10H13ClN2O3S

InChIKeyRKWGIWYCVPQPMF-UHFFFAOYSA-N

CAS Registry94-20-2

OBJECTIVES: I. Determine whether diverse mutations of the vasopressin-neurophysin II (AVP-NPII) gene cause autosomal dominant familial neurohypophyseal diabetes insipidus by directing the production of an abnormal preprohormone.
II. Determine whether the AVP-NPII gene-directed preprohormone accumulates and destroys magnocellular neurons because it cannot be folded and processed efficiently.

Start Date01 Dec 1995

Sponsor / Collaborator

National Center for Research Resources

[+1]

100 Clinical Results associated with Chlorpropamide

Login to view more data

100 Translational Medicine associated with Chlorpropamide

Login to view more data

100 Patents (Medical) associated with Chlorpropamide

Login to view more data

2,627

Literatures (Medical) associated with Chlorpropamide

01 Mar 2025·Asian Journal of Organic Chemistry

Deacylation of N‐Acylsulfonamides Mediated by Metal Triflimides

Author: Chen, Xin ; Wang, Xinyi ; Tian, Juan ; Peng, Ying ; Chen, Mengyun ; Sang, Dayong ; Yang, Shimin

AbstractN‐Acylsulfonamides play a significant role in organic and medicinal chemistry. The N‐deacylation of N‐acylsulfonamides is an important transformation that releases the sulfonamide structural motif. Herein, a metal triflimide‐catalyzed nonhydrolytic method for the deacylation of N‐acylsulfonamides is presented. Commercially available metal triflimides reactive for the N‐deacylation include Cu(NTf2)2, Zn(NTf2)2, Mg(NTf2)2, Ce(NTf2)3, and La(NTf2)3. A range of N‐acyl groups, including acetyl, propionyl, butyryl, isobutyryl, octanoyl, benzoyl, 2‐phenylacetyl, and sterically hindered pivaloyl are readily deblocked efficiently. A variety of functional groups, such as halogeno, keto, nitro, cyano, ether, and carboxylate, are tolerated intact.

01 Mar 2025·Analytical and Bioanalytical Chemistry

New robust and efficient liquid membranes for conductive vial electromembrane extraction of acids with low to moderate hydrophilicity in human plasma

Article

Author: Song, Chenchen ; Hay, Anne Oldeide ; Gaznawi, Somayeh ; Hansen, Frederik André ; Dowlatshah, Samira ; Hasvold, Grete

AbstractThe current paper reports two new, robust, and efficient conditions for electromembrane extraction of acidic substances from human plasma. Two systems were developed based on eutectic solvents: A1 (“A” for acid) comprised dodecyl methyl sulfoxide and thymol in 1:2 ratio (w/w) as liquid membrane, while A2 used [6-methylcoumarin:thymol (1:2)]:2-nitrophenyl octyl ether in 2:1 ratio (w/w). The performance of A1 and A2 was characterized by extraction of 31 acidic model analytes (pharmaceutical drugs and nutrients) spiked into 100 µL human plasma diluted 1:1 (v/v) with phosphate buffer pH 7.4. The acceptor solution was 50 mM NH4HCO3 buffer pH 10.0, and extraction was performed at an agitation rate of 750 RPM. Voltage and extraction time were 30 V for 30 min and 10 V for 20 min for A1 and A2, respectively. Under optimal conditions, A1 extracted analytes with 1.8 ≤ log P ≤ 6.0 with an average recovery (R) of 85.1%, while A2 extracted in a range of 0.5 ≤ log P ≤ 6.0 with an average recovery of 79.9%. Meanwhile, extraction current was low at 9 and 26 µA, respectively, which is indicative of good system robustness. Using UHPLC-MS/MS analysis of the acceptor solution, repeatability of the A1 and A2 methods was determined to be 2.8–7.7% and 3.3–9.4% for R > 40%, matrix effects were 82–117% and 84–112%, respectively, and linear calibration curves were obtained. The performance and compatibility with human plasma represent a major improvement over previous state-of-the-art liquid membranes for acidic analytes, namely 1-octanol.Graphical Abstract

01 Jan 2025·Journal of Chromatography B

Non-targeted screening of illegal added hypoglycemic drugs and their derivatives in functional foods using characteristic fragment ions scanning based on liquid chromatography-high-resolution mass spectrometry

Article

Author: Liu, Yajie ; Feng, Xuesong ; Wang, Xiujuan ; Du, Rongzhu ; Zhang, Feng ; Feng, Feng

Functional foods that are illegally adulterated with chemical hypoglycemic drugs or their derivatives pose serious risks to human health. However, the detection of these compounds is a challenge due to the unknown nature of their structures, particularly as many of these compounds are newly synthesized and lack standardized references. In this study, we developed a non-targeted screening strategy for detecting illegally added hypoglycemic drugs and their derivatives in oral solution and hard capsule functional foods. This strategy utilizes a self-established characteristic fragment ions mass spectrum database based on ultrahigh-performance liquid chromatography-quadrupole/orbitrap high-resolution mass spectrometry. Nine characteristic fragment ions were identified by analyzing the mass spectrometric fragmentation patterns of hypoglycemic drugs. Meanwhile, the precursor and fragment ions of 38 known hypoglycemic drugs were collected and incorporated into the mass database. The detection limits of hypoglycemic drugs in oral solution and hard capsule samples were 0.01-10 μg/L and 0.01-50 μg/kg, respectively. Applying the non-targeted method to 20 batches of suspicious samples, we found that 3 batches of samples contained illegal added drugs. Furthermore, we identified a previously unrecorded hypoglycemic drug not present in the mass database. These results indicate that the developed strategy is a powerful tool for the rapid and highly sensitive identification of both known and unknown hypoglycemic drugs, as well as their derivatives in functional foods.

1

News (Medical) associated with Chlorpropamide

29 Jul 2010

·www.medicaldesignandoutsourcing.com

Giant EagleÃ‚® Expands Free Prescription Program To Include Free Diabetes Medicines in Western Pennsylvania

PITTSBURGH, July 29 /PRNewswire/ — With diabetes affecting the lives of hundreds of thousands of people throughout Pennsylvania and Ohio, Giant Eagle®, Inc. has announced that it will begin offering five commonly prescribed medications for the treatment of type 2 diabetes at no cost to medical prescription holders. (Logo: ) (Logo: ) The program, which begins July 29, includes the medications Glimepiride, Glipizide, Glyburide, Metformin and Chlorpropamide which were previously available on the supermarket retailer’s $4 prescription program. The free diabetes medication program was piloted in Columbus and Toledo, Ohio in April and to date has provided nearly $190,000 in customer savings on diabetes medications. Diabetes has become a leading cause of death in the United States, with more than 90 percent of the 24 million Americans diagnosed with type 2 diabetes. As a result, Giant Eagle has jo ‘/>”/> SOURCE

100 Deals associated with Chlorpropamide

Login to view more data